Cover Image
市場調查報告書

白細胞介素1α:開發中產品分析

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365741
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素1α:開發中產品分析 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 49 Pages
簡介

本報告提供以白細胞介素1α為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素1α 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc.
  • Handok Inc.
  • XBiotech USA, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0172TDB

Summary

Global Markets Direct's, 'Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016', provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)
  • The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview
  • Therapeutics Development
    • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Stage of Development
    • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Therapy Area
    • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Indication
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Companies
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Handok Inc.
    • XBiotech USA, Inc.
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Drug Profiles
    • ABT-981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-2351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T2-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xilonix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Dormant Projects
  • Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Featured News & Press Releases
    • Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio
    • May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer
    • Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology's World Congress on Gastrointestinal Cancer
    • Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech's True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer
    • Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer
    • Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency
    • Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech's Marketing Authorization Application
    • Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament
    • Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium
    • Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer
    • Dec 07, 2015: XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer
    • Nov 23, 2015: XBiotech Provides Update on Phase III Oncology Study in Europe
    • Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting
    • Oct 02, 2015: XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human Antibody as a Cardiovascular Therapy
    • Aug 17, 2015: XBiotech Completes Enrollment for Xilonix Phase III Registration Study in Europe
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AbbVie Inc., H1 2016
  • Pipeline by Handok Inc., H1 2016
  • Pipeline by XBiotech USA, Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top